IBCL-123 inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

Laurie H. Sehn,Kai Hubel,Stefano Luminari,Antonio Salar,Bjorn E. Wahlin,Ajay K. Gopal,Christophe Bonnet,Shankara Paneesha,Marek Trneny,Hafsat Mashegu,Christine F. Lihou,Lulu Cheng,Christian W. Scholz

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览10

暂无评分

摘要

Primary endpoint is PFS (investigator-assessed [INV] by Lugano 2014 criteria) for patients with FL. Secondary endpoints include PFS (INV) in the overall population, PET-CR rate (INV) at 90 days after last treatment, and OS in patients with FL.

查看译文

关键词

IBCL,non-Hodgkin lymphoma,CD19,marginal zone lymphoma,follicular lymphoma,Phase III

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要